Frank Buchholz shares how his laboratory improves upon the latest gene editing techniques by designing programmable ...

CRSP is a speculative buy for aggressive investors, driven by the commercial launch and multibillion-dollar potential of ...

Scientists used CRISPR to reactivate uricase, an enzyme humans lost millions of years ago. Restoring the gene in liver cells ...

Another major buy was in INTELLIA THERAPEUTICS INC (NASDAQ:NTLA), with ARK purchasing 191,705 shares for around $2.18 million through its ARKK ETF. Similar to CRISPR, INTELLIA has seen increased ...

NtRON Bio announced today, following its recent U.S. patent application related to colorectal cancer using the IMPA™ phage engineering technology, it has now completed the filing of two patents for a ...

The Hershey Company, one of the largest chocolate manufacturers in the world and the producer of Reese's, Kisses, Kit Kat, ...

The results suggest that lung xenotransplantation could one day become an option, but they also point to how much more work ...

CRISPR Therapeutics has rallied on Casgevy progress, but overvaluation, early-stage pipeline, and lack of profits raise ...

There were more than 48,000 organ transplants in the U.S. in 2024, a 3.3% increase from 2023, according to Organ Procurement ...

The ability to correct disease-causing genetic mistakes using genome editors holds great promise in medicine, but it is not ...

Shares of CRISPR Therapeutics CRSP have rallied 41.4% in the past three months, driven by encouraging data from a study of ...

Natural killer (NK) cells became markedly better at killing cancer cells after scientists removed key gene targets identified through a new genome-wide CRISPR screening tool, according to new research ...